|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||3.18 / 10.21|
Seattle Genetics, Inc. (NASDAQ:SGEN) today announced that its wholly-owned subsidiary, Valley Acquisition Sub, Inc.
In recent trading, shares of Cascadian Therapeutics Inc have crossed above the average analyst 12-month target price of $8.50, changing hands for $10.05/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.
The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Cascadian Therapeutics, Inc.
Seattle Genetics, Inc. (Nasdaq:SGEN) and Cascadian Therapeutics, Inc.
Removes Requirement for Pediatric Clinical Studies to Support Tucatinib Market Authorization Application for Treatment of Metastatic Breast Cancer in Europe
Subgroup Analysis from Two Ongoing Combination Studies of Tucatinib Demonstrates Prolonged PFS Benefit Regardless of Presence of Brain Metastases or Patient Characteristics
Conference Call Scheduled for Today at 4:30 p.m. ET
The most recent short interest data has been released for the 09/15/2017 settlement date, which shows a 348,106 share decrease in total short interest for Cascadian Therapeutics Inc , to 1,937,349, a decrease of 15.23% since 08/31/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.
EMA Confirms Single HER2CLIMB Trial, If Positive, Could Support Approval
Investors in Cascadian Therapeutics Inc saw new options become available this week, for the February 2018 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 241 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.
Preclinical data from Chk1 inhibitor program and first presentation characterizing lead TIGIT antibody
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.